Search research articles
Contact Us
Filters
Showing results (261-270 of 299) with videos related to
Page
of 30
Sort By:
Targeted Oncology
|
June 24, 2022
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Mark R Middleton, Cheryl McAlpine, Victoria K Woodcock, et al.
Journal of Molecular Biology
|
January 8, 1999
The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins
C J Mann, T A Anderson, J Read, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2016
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
Jeffrey R Infante, Antoine Hollebecque, Sophie Postel-Vinay, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2016
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer
Shubham Pant, Suzanne F Jones, Carla D Kurkjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Cancer Chemotherapy and Pharmacology
|
January 19, 2017
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer
Jeffrey R Infante, Amita Patnaik, Claire F Verschraegen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
A M Menzies, M T Ashworth, S Swann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)
Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.
Vox Sanguinis
|
September 16, 2010
Adverse reactions during transfusion of thawed haematopoietic progenitor cells from apheresis are closely related to the number of granulocyte cells in the leukapheresis product
G A Martín-Henao, P M Resano, J M S Villegas, et al.
Page
of 30
Search research articles
Search
Showing results (261-270 of 299) with videos related to
Sort By:
Page
of 30
Targeted Oncology
|
June 24, 2022
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Mark R Middleton, Cheryl McAlpine, Victoria K Woodcock, et al.
Journal of Molecular Biology
|
January 8, 1999
The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins
C J Mann, T A Anderson, J Read, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2016
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
Jeffrey R Infante, Antoine Hollebecque, Sophie Postel-Vinay, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2016
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer
Shubham Pant, Suzanne F Jones, Carla D Kurkjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Cancer Chemotherapy and Pharmacology
|
January 19, 2017
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer
Jeffrey R Infante, Amita Patnaik, Claire F Verschraegen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
A M Menzies, M T Ashworth, S Swann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)
Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.
Vox Sanguinis
|
September 16, 2010
Adverse reactions during transfusion of thawed haematopoietic progenitor cells from apheresis are closely related to the number of granulocyte cells in the leukapheresis product
G A Martín-Henao, P M Resano, J M S Villegas, et al.
Page
of 30